Compare Diageo plc (DEO) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs TransMedics Group Inc — how do they compare? Diageo plc trades at $86.66 (market cap $47.67B), while TransMedics Group Inc trades at $79.53 (market cap $2.74B). The key difference: Diageo plc is far larger — about 17.4× TransMedics Group Inc's market cap, and Diageo plc pays a 2.3% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Diageo plc for 66 Days and TransMedics Group Inc for 24 Days on average.
| DEO | TMDX | |
|---|---|---|
Market Cap | $47.67B | $2.74B |
Volume | 893,372 | 949,331 |
Sector | Consumer Staples | Health |
52-Week High | $102.14 | $150.42 |
52-Week Low | $72.47 | $61.99 |
Typical Hold Time | 66 Days | 24 Days |
Enterprise Value | $68.09B | $3.13B |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $86.82, up 2.47% with bullish technical signals and strong analyst support. The stock shows solid fundamentals with consistent earnings beats, a 15.82% ROE, and improving cash flow trends. Recent corporate developments include a new CFO appointment and marketing initiatives supporting brand strength amid ongoing US business restructuring.
The outlook remains positive with 49% analyst buy ratings and cost-saving initiatives driving margin improvement. Key risks include US market volatility and regulatory challenges in India. The stock presents a compelling turnaround story with valuation support at current levels.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
